Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10623586 | 1.00 | ROCK2 (0.30) | ROCK2ROCK1 | |
| SCHEMBL13190682 | 1.00 | ROCK2 (0.30) | ROCK2ROCK1 | |
| SCHEMBL7746232 | 0.93 | — | — | |
| SCHEMBL21591990 | 0.80 | ROCK2 (0.33) | ROCK2ROCK1 | |
| SCHEMBL887223 | 0.80 | — | — | |
| SCHEMBL18560523 | 0.80 | ROCK2 (0.33) | ROCK2ROCK1 | |
| SCHEMBL28772429 | 0.78 | — | — | |
| SCHEMBL887222 | 0.76 | ADH1A (0.32) | — | |
| SCHEMBL22462729 | 0.76 | NOS3 (0.33) | ROCK2ROCK1 | |
| SCHEMBL8677451 | 0.76 | NOS3 (0.33) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806031-A2 | Method for searching for malodor control agent, malodor control agent, and malodor control method | Kao Corporation (JP) | 2014-11-26 | — | — | EP | claimed |
| US-20130216492-A1 | Method for Searching for Malodor Control Agent, Malodor Control Agent, and Malodor Control Method | KAO CORPORATION (JP) | 2013-08-22 | — | — | US | claimed |
| EP-2612923-A1 | METHOD FOR SEARCHING FOR MALODOR CONTROL AGENT, MALODOR CONTROL AGENT, AND MALODOR CONTROL METHOD | Kao Corporation (JP) | 2013-07-10 | — | — | EP | claimed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-22 | — | — | US | disclosed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | disclosed |
| EP-3966199-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2022-03-16 | — | — | EP | disclosed |
| WO-1999037611-A1 | HETEROCYCLIC AMIDINES AS CALLICREIN PROTEASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999037668-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
| EP-0918792-A1 | DIPEPTIDE BENZAMIDINE AS A KININOGENASE INHIBITOR | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006741-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998006740-A1 | DIPEPTIDE BENZAMIDINE AS A KININOGENASE INHIBITOR | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-4786332-A | TOBACCO PRODUCTS | GIVAUDAN CORPORATION (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0110362-B1 | FRAGRANCE AND FLAVOUR COMPOSITIONS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1988-04-20 | — | — | EP | disclosed |
| US-4606925-A | Flavoring with alkyl-substituted cyclohexyl and cyclohexenyl carboxylic acids | GIVAUDAN CORPORATION (US) | 1986-08-19 | — | — | US | disclosed |
| EP-0110362-A2 | Fragrance and flavour compositions | L. GIVAUDAN & CIE Société Anonyme (CH) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216492-A1 | Method for Searching for Malodor Control Agent, Malodor Control Agent, and Malodor Control Method | OR51E2, OR10J3, ORMDL3 | ROCK2 2577/4885ROCK1 3057/4885 |
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | MDM2, TP53, RECQL | ROCK2 2544/4885ROCK1 3180/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | ROCK2 4004/4885ROCK1 4002/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | ROCK2 2586/4885ROCK1 2665/4885 |
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | NPC1L1, NPC1, SREBF2 | ROCK2 2285/4885ROCK1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.